產品資訊 - Medical Meningococcal Polysaccharide Vaccine->aspalthic products

登入

加入會員

求助

Changchun Changsheng Life Sciences Ltd.

	Recommended Results

Medical Meningococcal Polysaccharide Vaccine

產品分類 :

化學->化學用品->aspalthic products

Medical Meningococcal Polysaccharide Vaccine

產品規格

Model No:	0.5 ml/vial

Country	CN
Minimum Order	5000
Payment Term	L/C,T/T

產品描述

The vaccine is indicated for active immunization against invasive meningococcal disease caused by epidemic Neisseria meningitidis serogroups A,C,Y,W135.


 [Description] 
The vaccine is a preparation of preparation polysaccharide antigens extracted from the culture of Neisseria meningitidis group ACYW135 respectively and Iyophilized after addition of an appropriate stabilizer. The final product looks like a white crisp cake. It shall dissolve in the accompanying Phosphate buffered saline (PBS) immediately, and turn into a clear liquid after reconstitution. 
Active constituent: Neisseria meningitidis group ACYW135 capsular polysaccharides. 
Subsidiary materials: All the components of subsidiary materials approved shall be listed. 
Vaccine diluent: Sterile, pyrogen-free PBS. 
[Specifications] 
0.5 ml of reconstituted vaccine per container. 0.5 ml per single human dose, containing  200μg of meningococcal polysaccharide (50μg of each polysaccharide of group A,C,Y,W135).


[Contraindications] 
(1) Subjects with known allergic reactions to any component of the vaccine. 
(2) Subjects with acute diseases, severe chronic diseases, chronic diseases at stage of acute attack or fever. 
(3) Subjects with encephalopathy, uncontrolled epilepsy,  and other progressive diseases of nervous system. 
[Precautions] 
(1) The vaccine should be administered with caution to the subjects with family or individual history of convulsion or those with chronic diseases, history of epilepsy,  allergic diathesis or nursing women. 
(2) Do not use the vaccine if the container shows abnormalities, such as crack, illegible label, and turbidity after reconstitution 
(3) Adrenaline should be available for first aid in case of severe anaphylactic reactions. The recipients shall be observed for at least 30 minutes on site after injection. 
(4) Freezing of vaccine is forbidden. 
[Storage] 
Store and ship the product at 2-8℃, protected from light. 
 
[Feature] 
Fill a gap in our country for the first time by developing 4-valent vaccine . 
Improve traditional purification technology to eliminate nucleic acid and protein. 
Improve WHO specifications and high harvest rate. Develop new type of stabilizer. Improve national quality standards. 
 
1.Group ACYW135                              
2.Group A+C                                       
3.prevent epidemic cerebrospinal meningitis                                                   


4.purified capsular polysaccharide antigens  
<img src="http://i.bosscdn.com/product/18/f2/13/d46381b9bd8edf65b150508726.png@watermark=2&color=I0ZGRkZGRg%3D%3D&type=ZHJvaWRzYW5zZmFsbGJhY2s%3D&size=22&p=9&t=80&text=Y3MtdmFjY2luZS5ib3NzZ29vLmNvbQ%3D%3D" title="-ACYW135" alt="-ACYW135" /> 
 



 
ccls-vaccine.com

其他類似產品